Loading
A phase 1 trial of tulmimetostat (CPI-0209) with carboplatin in platinum-sensitive recurrent ovarian cancer, run by Lan Coffman, now recruiting.
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer is a phase 1 interventional study registered as NCT05942300 by Lan Coffman, with Novartis Pharmaceuticals, National Cancer Institute (NCI) as collaborators; 30 participants are planned, it started on 2024-01-30; the registry gives 2028-07-31 as its primary completion date. Interventions recorded: CPI-0209, carboplatin. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Tulmimetostat, Novartis and the tag pipeline.
Shares Tulmimetostat, Novartis and the tag pipeline.
Shares Tulmimetostat and the tag pipeline.
Shares Carboplatin, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/